Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.66)
# 4,113
Out of 5,152 analysts
57
Total ratings
30.61%
Success rate
-29.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IKT Inhibikase Therapeutics | Initiates: Buy | $4 | $1.89 | +111.64% | 1 | Mar 4, 2026 | |
| AKTX Akari Therapeutics, | Initiates: Buy | $1 | $0.25 | +305.52% | 1 | Jan 5, 2026 | |
| ARDX Ardelyx | Assumes: Buy | $11 | $6.27 | +75.44% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $19.61 | +58.08% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.39 | +1,266.91% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $16.06 | +30.76% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $5.53 | -9.58% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.60 | +900.00% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $0.77 | +15,490.49% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $25.82 | -3.18% | 2 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $53.78 | - | 3 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,000 | $0.95 | +211,004.07% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.53 | +357.52% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $6.76 | +47.93% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $12.35 | +385.83% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $1.04 | +476.92% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.52 | +183.93% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $1.64 | +14,534.15% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $2.31 | +7,778.79% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $4,500 → $2,000 | $2.85 | +70,075.44% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $12.76 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.02 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $9.04 | +132.30% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $8.57 | +122,420.42% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $2.48 | +1,391.94% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $72.45 | +314.08% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $764.93 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $97.33 | -8.56% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $129.64 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $1.68 | +19,900.00% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.93 | +358.02% | 1 | Mar 19, 2020 |
Inhibikase Therapeutics
Mar 4, 2026
Initiates: Buy
Price Target: $4
Current: $1.89
Upside: +111.64%
Akari Therapeutics,
Jan 5, 2026
Initiates: Buy
Price Target: $1
Current: $0.25
Upside: +305.52%
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $6.27
Upside: +75.44%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $19.61
Upside: +58.08%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.39
Upside: +1,266.91%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $16.06
Upside: +30.76%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $5.53
Upside: -9.58%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.60
Upside: +900.00%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $0.77
Upside: +15,490.49%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $25.82
Upside: -3.18%
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $53.78
Upside: -
Feb 8, 2024
Initiates: Buy
Price Target: $2,000
Current: $0.95
Upside: +211,004.07%
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.53
Upside: +357.52%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $6.76
Upside: +47.93%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $12.35
Upside: +385.83%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $1.04
Upside: +476.92%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.52
Upside: +183.93%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $1.64
Upside: +14,534.15%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $2.31
Upside: +7,778.79%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $4,500 → $2,000
Current: $2.85
Upside: +70,075.44%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $12.76
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.02
Upside: -
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $9.04
Upside: +132.30%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $8.57
Upside: +122,420.42%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $2.48
Upside: +1,391.94%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $72.45
Upside: +314.08%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $764.93
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $97.33
Upside: -8.56%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $129.64
Upside: -
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $1.68
Upside: +19,900.00%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $3.93
Upside: +358.02%